


























































































































The evil of the patent foramen ovale:
we are seeing but the tip of the iceberg
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This editorial refers to ‘Patent foramen ovale closure vs.
medical therapy for cryptogenic stroke: a meta-analysis
of randomized controlled trials’†, by Y. Ahmad et al., on
page 1638.
The patent foramen ovale (PFO) is not considered a disease as it is
present in20–30% of the population. Yet, it is of significant concern.
Silent most of the time, the PFO can act up as a serious problem in its
Mister Hyde role as the fundamental reason for paradoxical embol-
ism engendering death, stroke, myocardial infarction, and peripheral
ischaemia. More likely than late spontaneous PFO closure during life,
selective mortality must be blamed for the well-documented
decreasing prevalence of the PFO with age.1,2 Observational data on
PFO carriers with thrombo-embolic events3 and long-term follow-
up of random patients with or without PFO closure4 underpin the
PFO’s licence to kill.
This issue of the journal includes an insightful meta-analysis encom-
passing all currently published randomized trials comparing PFO clos-
ure (mostly with continued medical therapy) with medical therapy
alone in patients with cryptogenic cerebral (or systemic) ischaemic
events.5 The superiority of PFO closure was the writing on the wall
from the first randomized trial and, even before, from comparative
data.6 However, it fell short of statistical significance in the initial
randomized trials, in part because intention-to-treat analyses were
used. Such analyses make little sense when implanted devices are at
stake. There is no placebo effect involved and a device that stays on
the shelf can hardly protect a patient against anything. Now, pre-
defined P-values have been reached by studies concentrating on high-
risk PFOs7,8 or following patients up for long enough;9 it took 3440
patients and more than 4 years of follow-up. Most turned their backs
on PFO closure when it missed a superiority trial with a P-value of
0.08 only to embrace it enthusiastically when the P-value has dropped
to 0.046 with extended follow-up.9 How strange is that? The positive
result with an occluder8 not reaching the closure rates of Amplatzer
occluders10 points out that a device may act as a filter even when it is
not watertight. This may not be the case after suture closure of the
PFO.
The meta-analysis in this issue highlights the crucial point that a
large PFO is more dangerous than a small PFO; why not throw in a
PFO with an atrial septal aneurysm opening the PFO with virtually
every heartbeat as well as a PFO with a Eustachian valve or a Chiari
network, guiding the clots from the inferior vena cava straight on to
the gap? The meta-analysis also expressly calls for rapid modifications
of the guidelines. Guidelines so far have not acknowledged the blatant
proof of non-inferiority of PFO closure vs. pure medical therapy, be-
cause the respective trials were designed as superiority trials. Failed
superiority trials cannot be used to establish equipoise according to
the modern stringent publication rigour. To the patient, a 15-min
painless ‘mechanical vaccination’11 must look more attractive than
lifelong blood thinners with their ever-accruing, and with increasing
age higher and more threatening, risk of bleeding. The guidelines sim-
ply do not condone such an offer to the patient. The outspoken plea
to correct that adds value to this meta-analysis in comparison with
recent similar publications.12–14 Focusing on large PFOs, in addition,
sounds trivial at first but has important implications. Large PFOs can
be found by simple transthoracic contrast echocardiography; small
PFOs are evident only by cumbersome and unpleasant transoesopha-
geal echocardiography. This puts a foot in the door of screening for
large PFOs with the purpose of primary prevention. People before
major surgery15, with a high risk for venous thrombo-embolism,3 or
of families with PFO problems might be a good place to start.
In real life, the frequency of PFO-mediated ischaemic events is
underestimated. Other causes are preferentially blamed, such as
atrial fibrillation, ruptured atherosclerotic plaques, or spontaneous
cerebral or coronary dissections. The PFO is almost invariably the
last on the list to be considered, let alone looked for. With a ratio of
coronary to cerebral blood flow of 1:3 (220 versus 750 mL/min),
one PFO-mediated myocardial infarction per three PFO-mediated
cerebral ischaemic events would make more sense than the
1:100 000 we seem to find in the literature. By the same token, in a
large field study, high rates of coincidental strokes and myocardial
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infarctions in patients with acute pulmonary embolism were found.16
The PFO, clearly documented as the reason for simultaneous embol-
ism in the pulmonary and systemic circulations nine years earlier,3
was appallingly not mentioned either in the paper or in the accom-
panying Editorial.17
Device PFO closure can be easily accomplished as a same-day pro-
cedure with minimal discomfort and risk. The patients can hold their
groin, themselves, like holding their elbow after donating blood, walk
out of the catheterization laboratory, and indulge in sports an hour
later. Post-treatment can be nothing or just a few weeks of low-dose
acetylsalicylic acid. Acute or late complications of concern are negli-
gible. Admittedly, all devices beget atrial arrhythmias, in rare cases
even atrial fibrillation, as apparent from all meta-analyses. However,
almost invariably that happens early, is transient, and does not require
oral anticoagulation.
The number needed to treat to prevent one stroke by PFO clos-
ure may be extrapolated from randomized trials to be as low as two
over their lifetime in patients with an index event. It may be specu-
lated that this is even lower in patients with a high-risk PFO, when
closing the PFO before rather than after an index event. Why would
anyone wait for a stroke or myocardial infarction in such a patient if
they can be prevented as easily as fixing a tooth, at a cost of less than
e10 000? On top of that, the patients may enjoy the collateral bene-
fits such as migraine improvement, decreased orthopnoea in platyp-
noea orthodeoxia, or improved physical performance in exercise
desaturation. These are examples of therapeutic rather than prevent-
ive PFO closure indications. Mind you, the collateral benefit works in
both directions.
After this meta-analysis, the indication for PFO closure for preven-
tion of a second cerebral ischaemic event after a cryptogenic index
event (what a misnomer, as a stroke in the presence of a PFO is no
more cryptogenic than a stroke in the presence of atrial fibrillation) is
cast in stone. Or should we say cast in ice? After all, what we see with
that indication is just the tip of the iceberg (Take home figure).
It can be harmful to withhold a therapy such as PFO closure until
long-term data have proved the benefit that had been plain to see for
a long time. The secret of the medical profession lies in anticipating
therapies that are reasonable and that are not, and to be proactive
accordingly. If one always waits for irrefutable evidence, one is sure
to deprive patients. In the case of the PFO, the cause of rare but dev-
astating events, that means that many preventable strokes, myocar-
dial infarctions, and even deaths happened and still happen while we
hesitate(d).
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Corrigendum doi:10.1093/eurheartj/ehx576
Online publish-ahead-of-print 4 October 2017
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Corrigendum to: Adenoviral intramyocardial VEGF-DDNDC gene transfer increases myocardial perfusion reserve in refractory angina
patients: a phase I/IIa study with 1-year follow-up [Eur Heart J (2017); 38(33): 2547–2555]
The authors of the above article wish to inform readers that the amount given in Table 4, column ‘P-value’, row ‘Lp(a) mg/dL’ has been
corrected from 0.203 to 0.023 via a post-publication correction.
The article has now been corrected online.
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